These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 20801850)

  • 1. Children deserve the same rights we do: the need for paediatric pulmonary arterial hypertension clinical drug development.
    Barst RJ
    Heart; 2010 Sep; 96(17):1337-8. PubMed ID: 20801850
    [No Abstract]   [Full Text] [Related]  

  • 2. The search for an oral prostanoid to treat pulmonary arterial hypertension continues. Are we getting any closer?
    Rich J; Hoeper MM
    Int J Clin Pract Suppl; 2009 Mar; (161):17-8. PubMed ID: 19178601
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Need for improved outcome measures in pulmonary arterial hypertension related to systemic sclerosis.
    Distler O; Behrens F; Huscher D; Foeldvari I; Zink A; Nash P; Denton CP; Humbert M; Matucci-Cerinic M; Seibold J; Rubin L; Furst DE
    Rheumatology (Oxford); 2006 Dec; 45(12):1455-7. PubMed ID: 16920751
    [No Abstract]   [Full Text] [Related]  

  • 4. Long-term outcomes in pulmonary arterial hypertension.
    Thenappan T; Palevsky HI
    Int J Clin Pract Suppl; 2009 Sep; (162):42-4. PubMed ID: 19624799
    [No Abstract]   [Full Text] [Related]  

  • 5. Tadalafil (Adcirca) for pulmonary arterial hypertension.
    Med Lett Drugs Ther; 2009 Nov; 51(1324):87-8. PubMed ID: 19890245
    [No Abstract]   [Full Text] [Related]  

  • 6. Cicletanine for the treatment of pulmonary arterial hypertension.
    Waxman AB; Lawler L; Cornett G
    Arch Intern Med; 2008 Oct; 168(19):2164-6. PubMed ID: 18955648
    [No Abstract]   [Full Text] [Related]  

  • 7. Pediatric pulmonary arterial hypertension--a review.
    Ferns SJ; Wehrmacher WH; Serratto M
    Compr Ther; 2009; 35(2):81-90. PubMed ID: 19618756
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Drug therapy of primary and secondary pulmonary hypertension].
    Olschewski H
    Herz; 2002 Aug; 27(5):463-7. PubMed ID: 12365287
    [No Abstract]   [Full Text] [Related]  

  • 9. Traditional and alternative designs for pulmonary arterial hypertension trials.
    Gomberg-Maitland M
    Proc Am Thorac Soc; 2008 Jul; 5(5):610-6. PubMed ID: 18625753
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Pulmonary arterial hypertension in collagen disease: findings of the German Network for Systemic Scleroderma].
    Halank M; Seyfarth HJ; Opitz C; Schmeisser A; Ewert R; Höffken G
    Dtsch Med Wochenschr; 2007 Feb; 132(7):337; author reply 338. PubMed ID: 17286224
    [No Abstract]   [Full Text] [Related]  

  • 11. Effectiveness of transition from intravenous epoprostenol to oral/inhaled targeted pulmonary arterial hypertension therapy in pediatric idiopathic and familial pulmonary arterial hypertension.
    Melnick L; Barst RJ; Rowan CA; Kerstein D; Rosenzweig EB
    Am J Cardiol; 2010 May; 105(10):1485-9. PubMed ID: 20451700
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pulmonary arterial hypertension in the pediatric age.
    Donti A; Formigari R; Ragni L; Manes A; Galiè N; Picchio FM
    J Cardiovasc Med (Hagerstown); 2007 Jan; 8(1):72-7. PubMed ID: 17255821
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcome of pediatric patients with pulmonary arterial hypertension in the era of new medical therapies.
    van Loon RL; Roofthooft MT; Delhaas T; van Osch-Gevers M; ten Harkel AD; Strengers JL; Backx A; Hillege HL; Berger RM
    Am J Cardiol; 2010 Jul; 106(1):117-24. PubMed ID: 20609658
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Continuous intravenous epoprostenol in pulmonary hypertension: the Israel experience.
    Bendayan D; Fink G; Aravot D; Ygla M; Bendov I; Bliden L; Nir A; Kramer MR
    Isr Med Assoc J; 2002 Apr; 4(4):255-8. PubMed ID: 12001697
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug discovery in pulmonary arterial hypertension: attacking the enigmatic root of a deadly weed.
    James White R; Lannan KL; Phipps RP
    Drug Discov Today; 2014 Aug; 19(8):1226-9. PubMed ID: 24769253
    [No Abstract]   [Full Text] [Related]  

  • 16. [A New Class of Drugs for the Treatment of Chronic Thromboembolic Pulmonary Hypertension].
    Cherniavskiĭ AM; Ivanov SN; Edemskiĭ AG; Cherniavskiĭ MA; Efimenko VG; Tarkova AR
    Kardiologiia; 2015; 55(2):102-6. PubMed ID: 26164996
    [No Abstract]   [Full Text] [Related]  

  • 17. Evaluating operability in adults with congenital heart disease and the role of pretreatment with targeted pulmonary arterial hypertension therapy.
    Dimopoulos K; Peset A; Gatzoulis MA
    Int J Cardiol; 2008 Sep; 129(2):163-71. PubMed ID: 18367267
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treprostinil for pulmonary hypertension.
    Vachiéry JL; Naeije R
    Expert Rev Cardiovasc Ther; 2004 Mar; 2(2):183-91. PubMed ID: 15151467
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long term imatinib treatment in pulmonary arterial hypertension.
    Souza R; Sitbon O; Parent F; Simonneau G; Humbert M
    Thorax; 2006 Aug; 61(8):736. PubMed ID: 16877696
    [No Abstract]   [Full Text] [Related]  

  • 20. [Pulmonary arterial hypertension. New therapeutic principles improve treatment of a rare condition].
    Ekmehag B
    Lakartidningen; 2009 Aug 19-25; 106(34):2057-61. PubMed ID: 19769147
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.